BeiGene Ltd.

187.49+0.5500+0.29%Vol 209.56K1Y Perf -3.92%
Dec 1st, 2023 16:00 DELAYED
BID185.00 ASK192.70
Open186.94 Previous Close186.94
Pre-Market- After-Market187.49
 - -  - -%
Target Price
245.60 
Analyst Rating
Strong Buy 1.44
Potential %
30.99 
Finscreener Ranking
★★★★     54.08
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★     45.69
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★+     47.48
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
24.93 
Earnings Rating
Strong Buy
Market Cap19.61B 
Earnings Date
8th Nov 2023
Alpha0.01 Standard Deviation0.14
Beta0.63 

Today's Price Range

186.11189.22

52W Range

156.56280.62

5 Year PE Ratio Range

-36.70-17.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
1.20%
1 Month
3.11%
3 Months
-10.52%
6 Months
-16.35%
1 Year
-3.92%
3 Years
-24.16%
5 Years
21.94%
10 Years
-

TickerPriceChg.Chg.%
BGNE187.490.55000.29
AAPL191.241.29000.68
GOOG133.32-0.6000-0.45
MSFT374.51-4.4000-1.16
XOM102.990.25000.24
WFC45.020.43000.96
JNJ158.383.72002.41
FB196.640.99000.51
GE122.500.70000.57
JPM156.840.76000.49
ValuationValueIndustryS&P 500US Markets
-11.60
5.48
24.68
605.70
-17.30
-16.70
5.52
44.78
20.67B
Forward PE-31.25
PEG-0.52
Financial StrengthValueIndustryS&P 500US Markets
3.70
4.10
0.05
0.15
-
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-33.10
-151.40
-146.50
-280.90
-86.01
RevenueValueIndustryS&P 500US Markets
1.04B
9.96
218.50
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-3.23-3.64-12.69
Q01 2023-3.94-3.3415.23
Q04 2022-4.22-4.29-1.66
Q03 2022-4.02-5.39-34.08
Q02 2022-4.23-5.56-31.44
Q01 2022-4.52-4.246.19
Q04 2021-4.79-6.16-28.60
Q03 2021-4.82-4.467.47
Earnings Per EndEstimateRevision %Trend
12/2023 QR-1.2940.55Positive
12/2023 QR-3.66-34.07Negative
12/2023 FY-6.9944.48Positive
12/2024 FY-5.9127.57Positive
Next Report Date-
Estimated EPS Next Report-3.16
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume209.56K
Shares Outstanding104.58K
Shares Float76.97M
Trades Count6.11K
Dollar Volume39.32M
Avg. Volume196.13K
Avg. Weekly Volume161.40K
Avg. Monthly Volume220.39K
Avg. Quarterly Volume206.59K

BeiGene Ltd. (NASDAQ: BGNE) stock closed at 186.94 per share at the end of the most recent trading day (a 2.08% change compared to the prior day closing price) with a volume of 186.74K shares and market capitalization of 19.61B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5300 people. BeiGene Ltd. CEO is John V. Oyler.

The one-year performance of BeiGene Ltd. stock is -3.92%, while year-to-date (YTD) performance is -15%. BGNE stock has a five-year performance of 21.94%. Its 52-week range is between 156.56 and 280.6199, which gives BGNE stock a 52-week price range ratio of 24.93%

BeiGene Ltd. currently has a PE ratio of -11.60, a price-to-book (PB) ratio of 5.48, a price-to-sale (PS) ratio of 24.68, a price to cashflow ratio of 605.70, a PEG ratio of -0.52, a ROA of -37.57%, a ROC of -44.67% and a ROE of -56.13%. The company’s profit margin is -86.01%, its EBITDA margin is -146.50%, and its revenue ttm is $1.04 Billion , which makes it $9.96 revenue per share.

Of the last four earnings reports from BeiGene Ltd., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-3.16 for the next earnings report. BeiGene Ltd.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BeiGene Ltd. is Strong Buy (1.44), with a target price of $245.6, which is +30.99% compared to the current price. The earnings rating for BeiGene Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BeiGene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BeiGene Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.35, ATR14 : 6.56, CCI20 : -28.96, Chaikin Money Flow : -0.09, MACD : 0.54, Money Flow Index : 48.40, ROC : -6.11, RSI : 51.43, STOCH (14,3) : 29.91, STOCH RSI : 1.00, UO : 51.77, Williams %R : -70.09), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BeiGene Ltd. in the last 12-months were: Capital Advisors, Ltd. Hillhouse (Sold 4 154 817 shares of value $823 480 568 ), HHLR ADVISORS, LTD. (Sold 4 154 817 shares of value $823 490 197 ), Oyler John (Sold 8 552 shares of value $2 127 538 ), Sanders Corazon (Sold 100 shares of value $18 074 ), Sanders Corazon (Corsee) D. (Sold 578 shares of value $105 381 ), Wang Julia Aijun (Sold 1 312 shares of value $238 341 ), Wang Lai (Sold 3 019 shares of value $583 636 ), Wang Xiaodong (Sold 811 620 shares of value $-8 793 ), Wang Xiaodong (Sold 61 771 shares of value $14 144 437 ), Wu Xiaobin (Sold 7 253 shares of value $1 565 482 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (77.78 %)
7 (77.78 %)
6 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (22.22 %)
2 (22.22 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.44
Strong Buy
1.44
Strong Buy
1.50

BeiGene Ltd.

BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.

CEO: John V. Oyler

Telephone: +1 345 949-4123

Address: c/o Mourant Governance Services (Cayman) Limited, Grand Cayman KY1-1108, , KY

Number of employees: 5 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

54%46%

Bearish Bullish

60%40%

 

News

Stocktwits